The Calidi Biotherapeutics Saga: Battling Through Q4 2023 with Missed EPS

Published On: March 15, 2024 10:59 pm

CLDI stock - CLDI Stock Earnings: Calidi Biotherapeutics Misses EPS for Q4 2023

Source: iQoncept / Shutterstock

Calidi Biotherapeutics (NYSEMKT:CLDI) unveiled its struggles in the realm of finance, bearing a disheartening -23 cents in earnings per share for the final quarter of 2023. This fiscal blow fell short of the -20 cents that analysts had anticipated.

The echo of disappointment resonated even further as the company revealed a stark void, absent of any revenue for the quarter.

InvestorPlace Earnings strides tirelessly to assimilate pivotal data from TradeSmith. Swiftly furnishing our readers with encapsulating insights such as earnings per share and revenue figures, the platform positions itself as the eponymous herald of financial events, all without human intrusion. For corrections or clarifications, kindly reach out to us at [email protected].

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/cldi-stock-earnings-calidi-biotherapeutics-for-q4-of-2023/.